Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Nyxoah (NYXH)

NASDAQ
Currency in USD
8.00
-0.26(-3.15%)
Closed
NYXH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
7.868.11
52 wk Range
4.0020.00
Key Statistics
Edit
Prev. Close
8
Open
8.08
Day's Range
7.86-8.11
52 wk Range
4-20
Volume
37.63K
Average Volume (3m)
68.39K
1-Year Change
61.94%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NYXH Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
13.90
Upside
+80.52%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Nyxoah Company Profile

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Employees
138
Market
Belgium

Nyxoah SWOT Analysis


Innovative OSA Solution
Nyxoah's Genio device offers unique features for obstructive sleep apnea treatment, targeting a $34 billion market opportunity across key regions
Financial Crossroads
Explore Nyxoah's mixed financial performance, with recent European market challenges offset by preparations for a crucial U.S. market entry
Regulatory Milestones
Learn about Nyxoah's progress towards FDA approval, with potential U.S. launch in late 2024 or early 2025 marking a pivotal growth phase
Market Dynamics
Analyst price targets range from $16 to $20, reflecting optimism about Nyxoah's potential to disrupt the OSA treatment landscape despite competition
Read full SWOT analysis
NYXH Full Pro Research
Institutional-Grade Stock Analysis
Understand how NYXH earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks

Nyxoah Earnings Call Summary for Q1/2024

  • Nyxoah reported 43% sales growth to u20ac4.3M in Q4, with u20ac1.8M in Q4 sales representing 87% sequential and 42% YoY growth
  • Company anticipates FDA approval and product launch by end of 2024, with final PMA module submission planned for Q2 2024
  • Strong cash position of u20ac58M provides runway into late 2024; Q4 cash burn was u20ac4.9M
  • Partnership with ResMed Germany expected to boost OSA therapy penetration; Nyxoah holds ~50% market share in Germany
  • Positive DREAM study results reported; detailed data to be presented at ISSS conference in September
Last Updated: 07-03-2024, 02:28 am
Read Full Transcript

Compare NYXH to Peers and Sector

Metrics to compare
NYXH
Peers
Sector
Relationship
P/E Ratio
−5.4x−0.9x−0.7x
PEG Ratio
1.61−0.030.00
Price/Book
2.7x2.2x2.6x
Price / LTM Sales
56.7x4.7x3.2x
Upside (Analyst Target)
95.8%108.8%43.2%
Fair Value Upside
Unlock14.6%6.8%Unlock

FAQ

What Is the Nyxoah (NYXH) Stock Price Today?

The Nyxoah stock price today is 8.00.

What Stock Exchange Does Nyxoah Trade On?

Nyxoah is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Nyxoah?

The stock symbol for Nyxoah is "NYXH."

What Is the Nyxoah Market Cap?

As of today, Nyxoah market cap is 301.93M.

What is Nyxoah Earnings Per Share?

The Nyxoah EPS is -1.73.

What Is the Next Nyxoah Earnings Date?

Nyxoah will release its next earnings report on 12 Mar 2025.

From a Technical Analysis Perspective, Is NYXH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.